Sugi Predict

Sugi Predict / Compounds / SCHEMBL11057710

SCHEMBL11057710

SCHEMBL11057710

CC(CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CCC4CCCC[C@]4(C)[C@H]3CC[C@]12C)C(=O)O

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPBAR1 Q8TDU6 8/20 0.75
▸ EPHA2 P29317 3/20 0.75
▸ HSD17B10 Q99714 3/20 0.75
▸ TDP1 Q9NUW8 3/20 0.75
▸ AKR1B10 O60218 2/20 0.75
▸ AKR1B1 P15121 2/20 0.75
▸ LMNA P02545 2/20 0.75
▸ EFNA1 P20827 1/20 0.75
▸ PSEN1 P49768 1/20 0.75
▸ PSEN2 P49810 1/20 0.75
▸ APH1B Q8WW43 1/20 0.75
▸ NCSTN Q92542 1/20 0.75
▸ APH1A Q96BI3 1/20 0.75
▸ PSENEN Q9NZ42 1/20 0.75
▸ MEN1 O00255 1/20 0.75
▸ KMT2A Q03164 1/20 0.75
▸ POLA1 P09884 1/20 0.57
▸ CDC25A P30304 1/20 0.57
▸ CASP7 P55210 3/20 0.56
▸ TP53 P04637 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1688731 1.00 GPBAR1 (0.75) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL11057706 1.00 GPBAR1 (0.75) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Carbamic Acid SCHEMBL27986182 0.88 EPHA2 (0.74) GPBAR1EPHA2HSD17B10TDP1AKR1B10
Carbamic Acid SCHEMBL27986186 0.88 EPHA2 (0.74) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL27833502 0.88 GPBAR1 (0.88) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL13516133 0.88 GPBAR1 (0.88) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL10624200 0.88 GPBAR1 (0.88) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL18576197 0.88 GPBAR1 (0.80) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL8971541 0.88 GPBAR1 (0.74) GPBAR1EPHA2HSD17B10TDP1AKR1B10
SCHEMBL22871910 0.87 GPBAR1 (0.86) GPBAR1EPHA2HSD17B10TDP1AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115724897-A Oxidation impurity removal method for cholestanic acid and derivatives thereof 四川澄华生物科技有限公司 2023-03-03 — — CN claimed
US-20220362398-A1 ADMINISTRATION OF SPHERICAL NUCLEIC ACIDS FOR OPHTHALMOLOGICAL USES EXICURE OPERATING COMPANY (US) 2022-11-17 — — US claimed
US-20220348917-A1 LIPOSOMAL SPHERICAL NUCLEIC ACID (SNA) CONSTRUCTS FOR SPLICE MODULATION EXICURE OPERATING COMPANY (US) 2022-11-03 — — US claimed
CN-114315945-A Impurity removal method for cholestanic acid and derivatives thereof 四川澄华生物科技有限公司 2022-04-12 — — CN claimed
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities THE BROAD INSTITUTE, INC. (US) 2026-03-17 — — US disclosed
US-20250376656-A1 MASSIVELY PARALLEL ON-CHIP CONSTRUCTION OF SYNTHETIC MICROBIAL COMMUNITIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-12-11 — — US disclosed
US-20250304974-A1 TLR9-TARGETED SPHERICAL NUCLEIC ACIDS HAVING POTENT ANTITUMOR ACTIVITY FLASHPOINT THERAPEUTICS, INC. (US) 2025-10-02 — — US disclosed
US-20250258146-A1 QUANTITATIVE DETECTION METHOD OF MULTIPLE METABOLITES IN BIOLOGICAL SAMPLE AND METABOLIC CHIP HUMAN METABOLOMICS INSTITUTE INC. (CN) 2025-08-14 — — US disclosed
US-20250195622-A1 METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY FACTOR BIOSCIENCE INC. 2025-06-19 — — US disclosed
CN-119463653-B Water-based steel structure anticorrosive paint and preparation method thereof 广东风铃树材料科技有限公司 2025-04-11 — — CN disclosed
CN-119454957-A Use of RINL antagonists in the prevention and treatment of hyperuricemia 厦门大学 2025-02-18 — — CN disclosed
CN-119463653-A Water-based steel structure anticorrosive paint and preparation method thereof 广东风铃树材料科技有限公司 2025-02-18 — — CN disclosed
WO-2022150369-A1 COMPOUNDS FOR THE TREATMENT OF BATTEN DISEASE EXICURE OPERATING COMPANY (US) 2022-07-14 — — WO disclosed
WO-2022147541-A1 COMPOUNDS FOR MODULATING SCN9A EXPRESSION EXICURE OPERATING COMPANY (US) 2022-07-07 — — WO disclosed
CN-114315945-A Impurity removal method for cholestanic acid and derivatives thereof 四川澄华生物科技有限公司 2022-04-12 — — CN disclosed
CN-112898370-B Method for extracting allochenodeoxycholic acid from duck bile 中山百灵生物技术股份有限公司 2022-04-12 — — CN disclosed
CN-114315945-A Impurity removal method for cholestanic acid and derivatives thereof 四川澄华生物科技有限公司 2022-04-12 — — CN disclosed
CN-114315945-A Impurity removal method for cholestanic acid and derivatives thereof 四川澄华生物科技有限公司 2022-04-12 — — CN disclosed
WO-2022036013-A1 TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (TNFRSF) AGONISTS, SPHERICAL NUCLEIC ACID (SNA) TLR9 AGONISTS AND CHECKPOINT INHIBITORS FOR ANTITUMOR THERAPY EXICURE OPERATING COMPANY (US) 2022-02-17 — — WO disclosed
US-4460509-A STEROIDS WITH HETERO RING SIDE CHAIN BETH ISRAEL MEDICAL CENTER (US) 1984-07-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195622-A1 METHODS AND PRODUCTS FOR NUCLEIC ACID PRODUCTION AND DELIVERY STING1, POLRMT, RARA GPBAR1 3465/4885EPHA2 2136/4885HSD17B10 2958/4885
US-12577526-B2 Massively parallel on-chip construction of synthetic microbial communities STUB1, SAMM50, CD14 GPBAR1 3144/4885EPHA2 1297/4885HSD17B10 742/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.